Management of hepatocellular carcinoma: From prevention to molecular targeted therapy

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 1-6

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma, prevention; Molecular targeted therapy; Sorafenib; Treatment algorithm

Indexed keywords

BRIVANIB; CISPLATIN; CONTRAST MEDIUM; FLUOROURACIL; GADOLINIUM DIETHYLENETRIAMINE PENTAACETIC ACID; INTERFERON; LAMIVUDINE; PERFLUBUTANE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

AFRICA; CANCER PREVENTION; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOUTHEAST ASIA; TREATMENT RESPONSE; ARTICLE; LIVER TUMOR; PATHOGENICITY; VIROLOGY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; PYRIDINES;

EID: 77954460673     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315222     Document Type: Review

References (41)

1. El-Serag HB: Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37:S88-S94.
2. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, Lo KJ, Shih YT: A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257: 2597-2603.
3. Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, Lu HC, Cheng SH, Wang YF, Wang CY, et al: Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3,464 infants of hepatitis B surface antigencarrier mothers. JAMA 1988; 260: 2231-2235.
4. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS: Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-908.
5. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS: Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284: 3040-3042.
6. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-1667.
7. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16: 265-271.
8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
9. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, et al: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184.
10. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181.
11. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, et al: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-99.
12. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, et al: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. He patology 1999; 29: 1124-1130.
13. Shindo M, Ken A, Okuno T: Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999; 85: 1943-1950.
14. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF: A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-994.
15. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
16. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl):2-15.
17. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
18. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, et al: Report of the 17th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
19. Inoue T, Kudo M, Hatanaka K, Takahashi S, Kitai S, Ueda T, Ishikawa E, Hagiwara S, Minami Y, Chung H, et al: Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with Sonazoid. Oncology 2008; 75(suppl 1):48-54.
20. Kudo M, Hatanaka K, Maekawa K: Defect reperfusion imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J Med Ultrasound 2008; 16: 169-175.
21. Kudo M, Hatanaka K, Chung H, Minami Y, Maekawa K: A proposal of novel treatmentassist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging (in Japanese). Kanzo 2007; 48: 299-301.
22. Kudo M, Hatanaka K, Maekawa K: Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumors. J Med Ultrasound 2008; 16: 130-139.
23. Hatanaka K, Kudo M, Minami Y, Maekawa K: Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008; 75(suppl 1):42-47.
24. Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Kitai S, et al: Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of Sonazoid-enhanced harmonic sonography. Oncology 2008; 75(suppl 1):99-105.
25. Minami Y, Kudo M: Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocelular carcinoma. World J Radiol 2009; 31: 86-91.
26. Kanematsu M, Kondo H, Goshima S, Tsuge Y, Watanabe H: Magnetic resonance imaging of hepatocellular carcinoma. Oncology 2008; 75(suppl 1):65-71.
27. Kim M, Choi J, Chung Y, Choi S: Magnetic resonance imaging of hepatocellular carcinoma using contrast media. Oncology 2008; 75(suppl 1):72-82.
28. Kudo M: Will Gd-EOB-MRI change the diagnostic algorithm for hepatocellular carcinoma? Oncology 2010;78(suppl 1):87-93.
29. Kudo M: The 2008 Okuda Lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 439-452.
30. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
31. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
32. The Cancer of the Liver Italian Program (CLIP) Investigators: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31: 810-845.
33. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215.
34. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-1405.
35. Tateishi R, Yoshida H, Shiina S, Imamura H, Hasegawa K, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, et al: Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-425.
36. Liver Cancer Study Group of Japan: General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Engl ed 2. Tokyo, Kanehara, 2003.
37. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan integrated staging score, the conventional Japan integrated staging score and the BALAD score. Oncology 2008; 75(suppl 1): 83-90.
38. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
39. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-442.
40. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
41. Okita K, Imanaka K, Chiba N, Tak W, Nakachi K, Takayama T, Suh D, Kumada H, Wada M, Kudo M: Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma treated after transarterial chemoembolization. ASCO Gastrointestinal Cancers Symposium Proceedings 2010, No 89 (LBA128).